Pegram M D, Pauletti G, Slamon D J
Department of Medicine, University of California Los Angeles School of Medicine, 90095, USA.
Breast Cancer Res Treat. 1998;52(1-3):65-77. doi: 10.1023/a:1006111117877.
Amplification of the HER-2/neu (c-erbB-2) gene resulting in overexpression of the p185HER-2 growth factor receptor occurs in approximately 25% of early stage breast cancers. HER-2/neu has been established as an important independent prognostic factor in early stage breast cancer in large cohorts of patients and in cohorts with very long (30 year) follow-up duration. New data are emerging to suggest that HER-2/neu may be useful not only as a prognostic factor but also as a predictive marker for projecting response to chemotherapeutics, antiestrogens, and therapeutic anti-HER-2/neu monoclonal antibodies. In this review we highlight recent data on HER-2/neu as a predictive marker of response to breast cancer therapy and discuss the clinical implications of this information. The difficulty in comparing results from different data sets due to the wide variety of reagents and technologies used to detect HER-2/neu amplification/overexpression in clinical specimens is also discussed. Finally, we report results from experimental models of HER-2/neu overexpression which have been used in an effort to understand the relationship between HER-2/neu and response to chemotherapeutics and antiestrogens in breast cancer.
HER-2/neu（c-erbB-2）基因扩增导致p185HER-2生长因子受体过表达，这一情况约在25%的早期乳腺癌中出现。在大量患者队列以及随访期长达30年的队列中，HER-2/neu已被确立为早期乳腺癌的一个重要独立预后因素。新的数据不断涌现，表明HER-2/neu不仅可能作为一个预后因素，还可能作为预测对化疗药物、抗雌激素药物以及治疗性抗HER-2/neu单克隆抗体反应的预测标志物。在这篇综述中，我们着重介绍关于HER-2/neu作为乳腺癌治疗反应预测标志物的最新数据，并讨论这些信息的临床意义。还讨论了由于用于检测临床标本中HER-2/neu扩增/过表达的试剂和技术种类繁多，导致不同数据集结果难以比较的问题。最后，我们报告HER-2/neu过表达实验模型的结果，这些模型已被用于努力理解HER-2/neu与乳腺癌对化疗药物和抗雌激素药物反应之间的关系。
